ES2546797T3 - Multímeros Zcytor17 receptores de citocinas - Google Patents
Multímeros Zcytor17 receptores de citocinas Download PDFInfo
- Publication number
- ES2546797T3 ES2546797T3 ES11151759.5T ES11151759T ES2546797T3 ES 2546797 T3 ES2546797 T3 ES 2546797T3 ES 11151759 T ES11151759 T ES 11151759T ES 2546797 T3 ES2546797 T3 ES 2546797T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- amino acid
- cytokine receptor
- seq
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010057085 cytokine receptors Proteins 0.000 title abstract description 20
- 102000003675 cytokine receptors Human genes 0.000 title abstract description 20
- 125000000539 amino acid group Chemical group 0.000 abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract description 3
- 229920001184 polypeptide Polymers 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 24
- 108090000695 Cytokines Proteins 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 13
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108700012920 TNF Proteins 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000004976 peripheral blood cell Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000003079 salivary gland Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 101800003471 Helicase Proteins 0.000 description 1
- 101800000355 Helicase nsp10 Proteins 0.000 description 1
- 101800002870 Helicase nsp13 Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- -1 MIP-1a Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000013718 rectal benign neoplasm Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35032502P | 2002-01-18 | 2002-01-18 | |
| US350325P | 2002-01-18 | ||
| US38910802P | 2002-06-14 | 2002-06-14 | |
| US389108P | 2002-06-14 | ||
| US43536102P | 2002-12-19 | 2002-12-19 | |
| US435361P | 2002-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2546797T3 true ES2546797T3 (es) | 2015-09-28 |
Family
ID=30003762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11151759.5T Expired - Lifetime ES2546797T3 (es) | 2002-01-18 | 2003-01-21 | Multímeros Zcytor17 receptores de citocinas |
| ES03761891T Expired - Lifetime ES2382800T3 (es) | 2002-01-18 | 2003-01-21 | Multímeros Zcytor17 receptores de citocinas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03761891T Expired - Lifetime ES2382800T3 (es) | 2002-01-18 | 2003-01-21 | Multímeros Zcytor17 receptores de citocinas |
Country Status (13)
| Country | Link |
|---|---|
| US (24) | US7494804B2 (enExample) |
| EP (3) | EP2338910B1 (enExample) |
| JP (2) | JP4511349B2 (enExample) |
| AT (1) | ATE547430T1 (enExample) |
| AU (1) | AU2003280410B8 (enExample) |
| CA (1) | CA2473733C (enExample) |
| CY (1) | CY1112787T1 (enExample) |
| DK (1) | DK1576112T3 (enExample) |
| ES (2) | ES2546797T3 (enExample) |
| IL (3) | IL226637A (enExample) |
| PT (1) | PT1576112E (enExample) |
| SI (1) | SI1576112T1 (enExample) |
| WO (1) | WO2004003140A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| AU7445900A (en) | 1999-09-27 | 2001-04-30 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, nr12 |
| US20030096339A1 (en) | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| SI2230299T1 (sl) | 2002-01-18 | 2012-07-31 | Zymogenetics Inc | Nov citokinski zcytor ligand |
| US7494804B2 (en) * | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
| US9738700B2 (en) | 2002-01-18 | 2017-08-22 | Zymogenetics Inc. | ZCYTOR17 heterodimeric cytokine receptor |
| JP2007068402A (ja) * | 2003-12-26 | 2007-03-22 | Bml Inc | 免疫応答調節蛋白質 |
| US20060269991A1 (en) * | 2004-11-03 | 2006-11-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | T cell protein and nucleotides encoding the same |
| CA2594502A1 (en) * | 2005-01-28 | 2006-08-03 | Zymogenetics Inc. | Homogeneous preparations of il-31 |
| CA2594490A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| AU2012202218B2 (en) * | 2005-02-14 | 2014-05-22 | National Jewish Medical And Research Center | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
| AU2006214325B2 (en) * | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| JP5065253B2 (ja) * | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| US7972776B2 (en) | 2005-11-15 | 2011-07-05 | Oncohealth Corporation | Protein chips for HPV detection |
| JP2009528264A (ja) | 2006-01-10 | 2009-08-06 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| CA2647846C (en) * | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CA2654623C (en) * | 2006-06-08 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease |
| US7851144B2 (en) | 2006-08-18 | 2010-12-14 | The University Of Washington | Compositions and methods for detecting cancer |
| US20100093076A1 (en) * | 2006-08-25 | 2010-04-15 | Moore Margaret D | Soluble il-27 receptor |
| PL2594586T3 (pl) * | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| US8968995B2 (en) | 2008-11-12 | 2015-03-03 | Oncohealth Corp. | Detection, screening, and diagnosis of HPV-associated cancers |
| US8865162B2 (en) | 2008-06-13 | 2014-10-21 | Oncohealth Corp. | Monoclonal antibodies against HPV proteins |
| US7799323B2 (en) | 2007-01-10 | 2010-09-21 | Zymogenetics, Inc. | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| WO2009041613A1 (ja) * | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗体定常領域改変体 |
| PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| MY185647A (en) | 2007-12-05 | 2021-05-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| KR20160074019A (ko) * | 2007-12-05 | 2016-06-27 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| CA2708251C (en) | 2007-12-07 | 2016-04-12 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
| KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
| EP4231014A3 (en) | 2010-11-30 | 2024-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| RS60050B1 (sr) | 2011-01-18 | 2020-04-30 | Bioniz Llc | Kompozicije za modulaciju aktivnosti gama-c-citokina |
| EP3456743B1 (en) | 2013-05-30 | 2021-08-18 | Kiniksa Pharmaceuticals, Ltd. | Oncostatin m receptor antigen binding proteins |
| US10464982B2 (en) | 2014-04-23 | 2019-11-05 | Emory University | Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto |
| HRP20250972T1 (hr) | 2015-04-14 | 2025-10-10 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak |
| MA43918A (fr) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| CN108135504B (zh) | 2015-09-23 | 2021-08-24 | 皇家飞利浦有限公司 | 具有可互换模块的模块化监控设备平台 |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10322165B2 (en) * | 2017-07-26 | 2019-06-18 | Academia Sinica | TIFA antagonists and their use for treating diseases |
| CR20200099A (es) | 2017-08-03 | 2020-07-24 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| AU2021297801A1 (en) * | 2020-06-24 | 2023-02-02 | Bioniz Therapeutics, Inc. | Antagonistic peptide targeting IL-2, IL-9, and IL-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders |
| WO2022049614A1 (ja) | 2020-09-01 | 2022-03-10 | 中外製薬株式会社 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4615974A (en) | 1981-08-25 | 1986-10-07 | Celltech Limited | Yeast expression vectors |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| CA1280080C (en) | 1984-12-06 | 1991-02-12 | Jacques Oberto | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| DE68926888T2 (de) | 1988-01-22 | 1997-01-09 | Zymogenetics Inc | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| JPH06504438A (ja) | 1990-12-13 | 1994-05-26 | イミュネックス・コーポレーション | 白血病抑制因子受容体 |
| JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
| US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
| CA2144651A1 (en) | 1992-09-14 | 1994-03-31 | Timothy J. Miller | Immortalized cells and uses therefor |
| US5906928A (en) | 1993-07-30 | 1999-05-25 | University Of Medicine And Dentistry Of New Jersey | Efficient gene transfer into primary murine lymphocytes obviating the need for drug selection |
| EP0745132A1 (en) | 1994-02-14 | 1996-12-04 | ZymoGenetics, Inc. | Method for preparing orphan receptor ligands |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5783672A (en) * | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| CN1075387C (zh) * | 1994-12-29 | 2001-11-28 | 中外制药株式会社 | 含有il－6拮抗剂的抗肿瘤剂的作用增强剂 |
| US6074849A (en) * | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| CA2237039A1 (en) | 1995-11-09 | 1997-05-15 | Zymogenetics, Inc. | Production of gad65 in methylotrophic yeast |
| US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| WO1998002565A1 (en) | 1996-07-17 | 1998-01-22 | Zymogenetics, Inc. | TRANSFORMATION OF $i(PICHIA METHANOLICA) |
| JP2002514049A (ja) | 1996-07-17 | 2002-05-14 | ザイモジェネティクス，インコーポレイティド | ピヒア・メタノリカの栄養要求性突然変異体の製造 |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| GB9819420D0 (en) | 1998-09-07 | 1998-10-28 | Glaxo Group Ltd | Novel receptor |
| DE60041697D1 (de) | 1999-06-01 | 2009-04-16 | Schering Corp | Säugetier-rezeptorproteine; ähnliche reagentien und methoden |
| ATE455852T1 (de) * | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| KR100840033B1 (ko) * | 1999-10-20 | 2008-06-19 | 제넨테크, 인크. | Ｔ 헬퍼 세포 매개 질환의 치료를 위한 ｔ 세포 분화의 조절 |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2412211A1 (en) | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| CA2412239C (en) * | 2000-06-26 | 2013-05-28 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
| US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| AU2002223182B2 (en) * | 2000-10-06 | 2007-08-30 | Immunex Corporation | Hematopoietin receptors HPR1 and HPR2 |
| WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
| SI2230299T1 (sl) * | 2002-01-18 | 2012-07-31 | Zymogenetics Inc | Nov citokinski zcytor ligand |
| US7494804B2 (en) | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
| WO2003072740A2 (en) * | 2002-02-25 | 2003-09-04 | Genentech, Inc. | Novel type-1 cytokine receptor glm-r |
| US7552497B2 (en) * | 2002-03-26 | 2009-06-30 | Colgate-Palmolive Company | Powered toothbrush with rotating sections |
| CA2594490A1 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
-
2003
- 2003-01-21 US US10/351,157 patent/US7494804B2/en not_active Expired - Fee Related
- 2003-01-21 DK DK03761891.5T patent/DK1576112T3/da active
- 2003-01-21 SI SI200332153T patent/SI1576112T1/sl unknown
- 2003-01-21 JP JP2004517500A patent/JP4511349B2/ja not_active Expired - Fee Related
- 2003-01-21 ES ES11151759.5T patent/ES2546797T3/es not_active Expired - Lifetime
- 2003-01-21 EP EP11151759.5A patent/EP2338910B1/en not_active Expired - Lifetime
- 2003-01-21 CA CA2473733A patent/CA2473733C/en not_active Expired - Fee Related
- 2003-01-21 ES ES03761891T patent/ES2382800T3/es not_active Expired - Lifetime
- 2003-01-21 WO PCT/US2003/001983 patent/WO2004003140A2/en not_active Ceased
- 2003-01-21 AT AT03761891T patent/ATE547430T1/de active
- 2003-01-21 PT PT03761891T patent/PT1576112E/pt unknown
- 2003-01-21 EP EP14185668.2A patent/EP2840089A1/en not_active Withdrawn
- 2003-01-21 AU AU2003280410A patent/AU2003280410B8/en not_active Ceased
- 2003-01-21 EP EP03761891A patent/EP1576112B1/en not_active Expired - Lifetime
-
2004
- 2004-07-15 IL IL226637A patent/IL226637A/en not_active IP Right Cessation
- 2004-07-15 IL IL163067A patent/IL163067A/en not_active IP Right Cessation
-
2006
- 2006-10-25 US US11/552,688 patent/US20070048833A1/en not_active Abandoned
- 2006-10-25 US US11/552,710 patent/US20070048834A1/en not_active Abandoned
- 2006-10-25 US US11/552,637 patent/US20070048831A1/en not_active Abandoned
- 2006-10-25 US US11/552,721 patent/US20070048835A1/en not_active Abandoned
- 2006-10-25 US US11/552,653 patent/US20070049530A1/en not_active Abandoned
- 2006-10-25 US US11/552,647 patent/US20070048832A1/en not_active Abandoned
- 2006-10-26 US US11/553,219 patent/US20070140963A1/en not_active Abandoned
- 2006-10-26 US US11/553,241 patent/US20070140964A1/en not_active Abandoned
- 2006-10-27 US US11/553,821 patent/US20070048222A1/en not_active Abandoned
- 2006-10-27 US US11/553,835 patent/US20070048223A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/431,623 patent/US20100266597A1/en not_active Abandoned
- 2009-04-29 US US12/432,286 patent/US20100266499A1/en not_active Abandoned
- 2009-06-12 US US12/484,019 patent/US20090274694A1/en not_active Abandoned
- 2009-08-21 US US12/545,770 patent/US20100055101A1/en not_active Abandoned
- 2009-10-27 JP JP2009246276A patent/JP2010043120A/ja active Pending
-
2011
- 2011-04-13 US US13/085,645 patent/US20110318354A1/en not_active Abandoned
-
2012
- 2012-02-27 US US13/405,916 patent/US20120264168A1/en not_active Abandoned
- 2012-05-25 CY CY20121100477T patent/CY1112787T1/el unknown
-
2013
- 2013-01-14 US US13/741,036 patent/US8647866B2/en not_active Expired - Fee Related
- 2013-05-29 IL IL226637A patent/IL226637A0/en unknown
- 2013-12-23 US US14/138,199 patent/US9212213B2/en not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/856,588 patent/US20160002340A1/en not_active Abandoned
-
2017
- 2017-03-31 US US15/476,006 patent/US20170204190A1/en not_active Abandoned
- 2017-07-12 US US15/648,203 patent/US10227415B2/en not_active Expired - Fee Related
- 2017-09-11 US US15/701,214 patent/US20170369580A1/en not_active Abandoned
-
2018
- 2018-08-10 US US16/100,485 patent/US20180346584A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2546797T3 (es) | Multímeros Zcytor17 receptores de citocinas | |
| Hess et al. | Decidual stromal cell response to paracrine signals from the trophoblast: amplification of immune and angiogenic modulators | |
| Simón et al. | Localization of interleukin-1 type I receptor and interleukin-1 beta in human endometrium throughout the menstrual cycle | |
| Buonocore et al. | Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans | |
| Kaneko et al. | Fusion of an ETS‐family gene, EIAF, to EWS by t (17; 22)(q12; q12) chromosome translocation in an undifferentiated sarcoma of infancy | |
| Lutfalla et al. | A new member of the cytokine receptor gene family maps on chromosome 21 at less than 35 kb from IFNAR | |
| Clay et al. | Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment | |
| Albertsen et al. | A physical map and candidate genes in the BRCA1 region on chromosome 17q12–21 | |
| US6268221B1 (en) | Melanocyte stimulating hormone receptor and uses | |
| DE69510810T2 (de) | Lamanin-ketten: diagnostische und therapeutische verwendung | |
| Krizman et al. | Construction of a representative cDNA library from prostatic intraepithelial neoplasia | |
| Weaver-Feldhaus et al. | Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. | |
| ES2344636T3 (es) | Marcadores microsatelites de repeticiones mononucleotido para detectar la inestabilidad de los microsatelites. | |
| Maguer-Satta et al. | BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia | |
| Prchal et al. | A novel clonality assay based on transcriptional analysis of the active X chromosome | |
| Schalken et al. | Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis | |
| Helmke et al. | Melanoma metastasis is associated with enhanced expression of the syntenin gene | |
| WO2005075636A1 (en) | Molecular markers associated with metanephric development and renal progenitors | |
| Wrzeszczynski et al. | Whole genome sequencing-based discovery of structural variants in glioblastoma | |
| Kluck et al. | The human interleukin-6 receptor α chain gene is localized on chromosome 1 band q21 | |
| Elkahloun et al. | In situ gene expression analysis of cancer using laser capture microdissection, microarrays and real time quantitative PCR | |
| Guevara-Fujita et al. | Chromosomal assignment of seven genes on canine chromosomes by fluorescence in situ hybridization | |
| Clark et al. | The Tnfrh1 (Tnfrsf23) gene is weakly imprinted in several organs and expressed at the trophoblast-decidua interface | |
| KR20190078715A (ko) | 암 유전자 및 항암제 대사 관련 유전자 변이 분석을 위한 차세대 염기 서열 분석(ngs) 기반 혼합 진단 패널 | |
| WO2002012554A2 (de) | Diagnose von mit cd24 assoziierten krankheiten |